Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-CoV-2.
Presently, data on the real-world effectiveness and optimal dosage of favipiravir for …

Background Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) have
continually grown as a global public health threat, with significant mortality rates observed …

Purpose To investigate the epidemiology of carbapenem-resistant Enterobacterales (CRE)
colonization or CRE infection relative to the natural history and clinical course of CRE …

Background. Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity
against SARS-CoV-2. Presently, data on the effectiveness and optimal dosage of favipiravir for …

The article presents a case study of a 45-year-old man with prolonged fever; diagnosis of
pneumocystis jirovecii pneumonia, cryptococcal meningitis and cytomegalovirus retinitis; and …

Background. Presently, data on effectiveness of triple combination of favipiravir, chloroquine-based
agents and protease inhibitors for treatment of covid-19 patients with pulmonary …

Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-CoV-2.
Presently, data on the real-world effectiveness and optimal dosage of favipiravir for …

Objectives Historically, colistin has been considered a last-line therapeutic option against
multidrug-resistant Gram-negative bacterial infections. However, chromosomally-encoded and …

Background: The main cause of the COVID-19 outbreak is transmission from asymptomatic
patients. Healthcare workers are high risk groups who were likely to be infected. The …